Test Price
1,600 AED✅ Home Collection Available
NPM1 & FLT3 Mutation Analysis in AML | 1600 AED
Executive Summary & Core Metrics
- Diagnostic Precision: 99.9% Diagnostic Sensitivity through ISO 9001:2015 Accredited Sanger Sequencing, ensuring unambiguous detection of NPM1 and FLT3 mutations critical for acute myeloid leukemia (AML) prognosis and targeted therapy selection.
- Premium Logistics: Hospital extraction only – bone marrow aspiration is conducted strictly within an accredited hospital facility by a specialist; mobile home phlebotomy is disabled for safety and sample integrity.
- Clinical Guidance: Complimentary telephonic post-test clinical guidance available to discuss results with your treating hematologist or oncologist.
- Insurance & Billing: Direct billing verification and pre-approval assistance via WhatsApp at +971 54 548 8731.
- UAE Compliance: Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
NPM1 & FLT3 Mutation Analysis is a high-precision Sanger Sequencing assay designed to detect somatic mutations in the nucleophosmin 1 (NPM1) and fms-related tyrosine kinase 3 (FLT3) genes from bone marrow aspirate or peripheral blood. This test is essential for risk stratification and therapeutic decision-making in acute myeloid leukemia (AML), as these mutations directly inform prognosis and eligibility for targeted therapies such as midostaurin and gilteritinib.
| Parameter | Our NPM1 & FLT3 Test | Closest Alternative (NGS Panel) |
|---|---|---|
| Methodology | Sanger Sequencing (Gold Standard for targeted mutations) | Next-Generation Sequencing (broad gene panel) |
| Analytical Sensitivity | Detection limit ~5% variant allele frequency | Varies ~2-5% depending on coverage depth |
| Turnaround Time | 7–8 working days | 10–14 working days (typical) |
| Cost (AED) | 1,600 | 2,500 – 4,000 |
| DHA Compliance | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | Variable |
Physician Insight & Safety Protocols
"In my clinical practice managing AML patients, concurrent NPM1 and FLT3 testing via Sanger sequencing provides the fastest, most actionable genetic blueprint for immediate treatment decisions. While NGS panels offer breadth, they often introduce delays that are unacceptable in acute leukemia. This targeted testing allows me to swiftly determine eligibility for FLT3 inhibitors and accurately stratify prognostic risk, ensuring no window of opportunity is missed."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠️ Critical Advisory: Do not discontinue, initiate, or modify any prescribed medication or treatment plan based solely on these results. All therapy changes must be made by your qualified hematologist or oncologist in the context of the full clinical picture.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusions: This test requires a physician's prescription and is strictly intended for patients with clinical suspicion of hematologic malignancy. It is not valid for routine screening, surgery clearance, travel certification, or pregnancy evaluation.
- Red Flags (Seek Immediate Emergency Care): Sudden onset of severe fatigue, pallor, unexplained bruising or bleeding, persistent fever >38.3°C, bone pain, or night sweats. These signs may indicate acute leukemia and require urgent comprehensive medical evaluation, not solely genetic testing.
- Sample Integrity: Bone marrow aspirate or peripheral blood must be collected by a qualified specialist and transported immediately in appropriate EDTA tubes to ensure RNA/DNA integrity. Delays beyond 24 hours may compromise result accuracy.
Patient FAQ & Clinical Guidance
1. What exactly does the NPM1 and FLT3 mutation test reveal about my leukemia?
This test identifies specific genetic changes (mutations) in your leukemic cells that help predict how aggressive the disease is and whether you are likely to respond to targeted oral therapies such as midostaurin or gilteritinib. It is a cornerstone of modern AML management.
2. Is the bone marrow collection painful, and can it be done at home?
Bone marrow aspiration is performed under local anesthesia by a qualified specialist. It typically causes mild discomfort and pressure. For safety and sample quality, this procedure must be conducted strictly within an accredited hospital or clinical facility. Home collection is not available for bone marrow biopsies.
3. Can this test result be used for travel or surgery clearance?
No. This test is intended exclusively for clinical decision-making in patients with suspected or confirmed hematologic cancers. It is not valid for travel certification, pre-surgical assessment, or general wellness screening.
4. How should I prepare for the sample collection?
No specific preparation is needed for the bone marrow aspiration itself, though your doctor may advise you on fasting if sedation is planned. Ensure you bring a complete list of current medications and your physician's referral form. The procedure will be explained in detail by the specialist before collection.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection Framework
DNA Labs UAE strictly adheres to the highest standards of medical data privacy and security as mandated by UAE federal laws. All genetic and clinical data generated from this test are processed and stored in full compliance with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring your medical records and genetic information are safeguarded against unauthorized access or disclosure.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, which governs the secure handling and electronic transfer of health data across UAE healthcare platforms.
- Federal Decree-Law No. 4 of 2016 on Medical Liability, confirming that all clinical procedures, including bone marrow aspiration and genetic testing, are performed under strict medico-legal standards of care and patient consent.
Our DHA Facility License (No. 1143) and ISO 9001:2015 certification (INT/EGQ/2509DA/3139) further demonstrate our unwavering commitment to quality and regulatory compliance.
Clinical & Logistical Metadata
| Test Name | NPM1 & FLT3 Mutation Analysis (Sanger Sequencing) |
| Price (AED) | 1,600 |
| Turnaround Time | 7–8 working days |
| Sample Type / Matrix | Hospital Extraction Only – Bone marrow aspirate or peripheral blood collected strictly within an accredited hospital facility by a qualified specialist; mobile home phlebotomy is disabled for safety. |
| Methodology Used | Sanger Sequencing (Gold Standard for targeted mutation detection) |
| ICD-10-CM Code | C92.0 (Acute myeloid leukemia), D46.9 (Myelodysplastic syndrome, unspecified) |
| LOINC Code | 92814-7 (NPM1 gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians